Background: In locally advanced squamous cell esophageal cancer, concurrent chemoradiotherapy (CRT) is the standard of care, as it especially improves local control and overall survival compared to radiotherapy alone. In contrast, treatment strategies for esophageal adenocarcinoma often parallel those used in gastric cancer, particularly regarding systemic therapy. Objectives: This study aimed to evaluate the clinicopathological factors affecting event-free survival (EFS) and overall survival (OS) following trimodality treatment in patients with non-metastatic esophageal cancer. Methods: A total of 155 patients diagnosed with esophageal cancer between March 2019 and November 2025 were retrospectively analyzed. Response to concurrent chemoradiotherapy was assessed via thoracic magnetic resonance imaging and endoscopic biopsy. Results: Clinicopathological analysis showed that male sex, the presence of lymphovascular invasion, adenocarcinoma histology, poor pathological response and advanced-stage tumors were significantly associated with worse EFS (all p < 0.001). In multivariate analysis, stage IVa disease was identified as an independent predictor of both mortality and relapse, with an approximately five-fold increased risk of death (p = 0.028) and relapse (p = 0.019). Patients with squamous cell carcinoma had a longer median EFS compared to those with adenocarcinoma (18 vs. 8.4 months, respectively). The 3- and 5-year OS rates were 59.2% and 56% in patients with squamous cell carcinoma, compared with 40% and 26% in those with adenocarcinoma, respectively. Conclusions: Survival outcomes were more favorable in patients with squamous cell histology and those diagnosed at an early stage. Active surveillance may be considered in selected patients with a complete clinical response to avoid the perioperative mortality associated with surgery.

Oküler melanomlar, kutanöz tümörlerden sonra ikinci en sık görülen malign melanom türü olup yetişkinlerde birincil göz içi malignitelerin başında gelir. Bu tümörler büyük oranda üveal yapıdan (koroid, siliyer cisim, iris) köken alırken, daha az oranda konjonktivada ortaya çıkar. Üveal melanom genellikle 60 yaş civarında teşhis edilir ve açık ten ile göz rengi gibi genetik risk faktörleriyle ilişkilidir; ancak ultraviyole ışığın etkisi kanıtlanmamıştır. Klinik belirtiler tümörün boyutuna göre değişmekle birlikte görme kaybı ve fotopsi gibi semptomları içerir. Teşhiste oftalmoskopi ve B-Scan ultrasonografi gibi klinik yöntemler öne çıkarken, birincil tedavide plak radyoterapisi (brakiterapi) ve seçili vakalarda enükleasyon uygulanır. Üveal melanom, özellikle karaciğere yavaş ama erken metastaz yapma eğilimindedir. Metastatik hastalıkta HLA-A*02:01 pozitif hastalarda Tebentafusb ilk seçenektir. Diğer yandan, konjonktival melanomlar oküler melanomların %5'ini oluşturur ve moleküler açıdan üveal formdan ziyade kutanöz melanomlara benzer. Konjonktival melanomda BRAF ve KRAS mutasyonları sık görülürken, tedavisinde geniş lokal eksizyon, kriyoterapi ve immün kontrol noktası inhibitörleri (PD-1/CTLA4) tercih edilmektedir. Ocular melanomas represent the second most common type of malignant melanoma after cutaneous tumors and constitute the most frequent primary intraocular malignancy in adults. While the vast majority originate from the uveal tract (choroid, ciliary body, iris), a smaller fraction arises from the conjunctiva. Uveal melanoma is typically diagnosed around the age of 60 and is strongly associated with risk factors such as fair skin and light eye color, whereas the role of ultraviolet light remains unproven. Clinical presentation depends on tumor size and location, often manifesting as vision loss or photopsia. Diagnosis primarily relies on ophthalmoscopy and B-Scan ultrasonography. Plaque radiotherapy (brachytherapy) serves as the primary treatment modality, while enucleation is reserved for advanced cases. Despite localized treatments, uveal melanoma carries a high risk of systemic metastasis, predominantly targeting the liver. In metastatic settings, Tebentafusp is the preferred frontline systemic therapy for HLA-A*02:01 positive patients. Conversely, conjunctival melanomas account for only 5% of ocular melanomas and exhibit genomic features closer to cutaneous melanomas. They frequently harbor BRAF and KRAS mutations, and their management combines wide local excision with cryotherapy and immune checkpoint inhibitors.

Background and Objectives: Evidence regarding predictors of pathological response and long-term outcomes in older patients receiving perioperative FLOT chemotherapy for resectable gastric or gastroesophageal junction cancer remains limited. We aimed to identify factors associated with pathological response and survival in patients aged ≥65 years treated with neoadjuvant FLOT. Materials and Methods: This retrospective single-center study included 86 consecutive patients (median age, 69 years; 72.1% male) aged ≥65 years with resectable gastric or gastroesophageal junction adenocarcinoma who underwent neoadjuvant FLOT chemotherapy followed by curative-intent gastrectomy. Major pathological response was defined as College of American Pathologists tumor regression grade (CAP TRG) 0–1. Logistic regression analyses were performed to identify predictors of pathological response. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards regression analyses. Results: Overall, 14 patients (16.3%) achieved a major pathological response. Body mass index (BMI) ≥ 25 kg/m² (OR 5.13, p = 0.04) was independently associated with a major pathological response. During a median follow-up of 29.2 months, 39 patients (45.3%) developed recurrence and 35 (40.7%) died. ECOG performance status (ECOG PS) ≥ 1 was independently associated with both inferior DFS (HR = 2.76, p = 0.02) and OS (HR = 2.52, p = 0.045). In addition, ypN stage 2–3 (HR = 2.58, p = 0.008) was independently associated with worse DFS, whereas positive surgical margins were independently associated with worse OS (HR = 2.62, p = 0.02). Conclusions: In older patients with resectable gastric or gastroesophageal junction adenocarcinoma treated with perioperative FLOT chemotherapy, baseline BMI was independently associated with major pathological response, whereas ECOG PS and postoperative pathological factors were independently associated with survival. These findings highlight the importance of careful patient selection and individualized multimodal treatment in this population.

Klinik Araştırma Türleri Ayşegül SAKİN Geleneksel Çin Tıbbı Kubilay KARABOYUN Ginseng Jamshid HAMDARD Zerdeçal Ekstresi (Kurkumin/Turmeric) Saadet SİM YILDIRIM Kara Kohoş Otu (Cimicifuga Racemosa) Merve ÖZKAN Ekinezya (Echinacea Purpurea) Abdussamet ÇELEBİ Gingko Biloba Mert ERCİYESTEPE Flavonoidler Aslı GEÇGEL Yeşil Çay (Camellia Sinensis) Berkan KARABUĞA Ada Çayı (Salvıa Offıcınalıs) Seval ORMAN Essiac Çayı Shamkhal SAFAROV Çörek Otu (Nigella Sativa) Özden DEMİR Deve Dikeni (Silybum Marianum) Gamze SERİN ÖZEL Isırgan Otu (Urtica Dioica) Gülhan DİNÇ Andız (Inula Viscoza) Azer GÖKMEN Garcinol (Garcinia Cambogia) Serkan GÜLCÜ Nar kabuğu (Punica Granatum) Orçun CAN Kişniş (Coriandrum Sativum) Nurbanu İNCİ Biberiye (Rosmorinus Officinalis) Pınar ÇOBAN EŞDUR Zencefil (Zingber Officinale) Nadiye SEVER Nane (Mentha Piperita) Okan AYDIN Papatya (Chammomilla Recutita) Buket ŞAHİN ÇELİK Zeytinyağı (Virgin Olive Oil) Hayriye TANİN DEMİRCİ Kekik (Thymus/ Thyme/ Thymus Vulgaris) Ahmet Emin ÖZTÜRK Ökse Otu (Mistletoe) Hacı ARAK Keçiboynuzu (Ceratonia Siliqua) Murad GULIYEV Hurma (Phoenix Dactylifera) Akif DOĞAN İncir (Ficus Carica) Erkam KOCAASLAN Sarımsak (Allium Sativum) ve Soğan (Allium Cepa) Ahmet AYDIN Sabin GÖKTAŞ AYDIN Kava Kava (Piper Methysticum) Yıldız GARİP BİLEN Meyan kökü (Glyctrrhiza Uralensis) Altay ALİYEV Sarı Kantaron (Hypericum Perforatum) Mustafa ERSOY Kedi Otu (Valeriana Officinalis) Mürsel SALİ Geven Otu (Astragalus) Harun MUĞLU Aloe Vera Emir Gökhan KAHRAMAN Kenevir (Cannabis) Alperen Akansel ÇAĞLAR Graviola Meyvesi ve Yaprağı (Annona Muricata Leaf) Seda SALİ Reişi Mantarı (Reishi Shiitake Maitake) Alper COŞKUN Likopen (Solanum Lycopersicum) Oğuzcan ÖZKAN Modifiye Narenciye Pektini (Pectin) Sümeyra DERİN Bayır Turbu (Armoracia Rusticana) Yasin SEZGİN Akgünlük (Boswellia Serrata) Esra Şazimet KARS Balık Yağı / Omega Yağları Nargiz MAJİDOVA Melatonin Aykut TURHAN Köpekbalığı Kıkırdağı Ömer GENÇ Hidrazin Doğan BAYRAM Koenzim Q10 Ekin KONCA KARABUĞA Resveratrol İbrahim BİLEN Timus Ekstresi Mehmet Cem FİDAN Bal ve Propolis Eyüp ÇOBAN Mineral Takviyesi Ömer Faruk ELÇİÇEK Kefir ve Kanser Melek ÖZDEMİR Alfa Lipoik Asit Hülya ODABAŞI BÜKÜN Glutatyon Fatma Pınar AÇAR Mavi Akrep Zehiri (Rhopalurus Junceus) Muslih ÜRÜN Spirulina Özge YALICI Chlorella Şermin DİNÇ SONUŞEN C Vitamini (Askorbik Asit) Murat GÜNALTILI Vitamin D Yunus Emre ALTINTAŞ A Vitamini ve Karotenler Tanju KAPAĞAN Vitamin E Güner AKGÜNER B6 Vitamini (Pridoksin) Erdem SÜNGER B12 Vitamini (Kobalamin) Goncagul AKDAG Folik Asit Selen KANTARCI KARATAŞ Multivitamin Kompleksleri Ezgi TÜRKOĞLU Ketojenik Diyet Ömer Faruk KUZU Akdeniz Diyeti Osman Bilge KAYA Aralıklı Oruç Ülviye OFLAS Vegan Beslenme Oğuzcan KINIKOĞLU Akupunktur Tedavisi Gülin Alkan ŞEN Yoga/Meditasyon Mehmet Nezir RAMAZANOĞLU Hypnotherapy Zeynep ALTUNDAĞ DERİN Aromatherapy Pınar PEKER Ayurveda Salih TÜNBEKİCİ Hacamat (Cupping Therapy) Mahmut KARA Ozon Tedavisi Murat ALAN üm Vücut Hipertermi (Whole Body Hyperthermia) Şaban SEÇMELER